​

Inhibikase Therapeutics Ownership | Who Owns Inhibikase Therapeutics?

OverviewRevenueFinancialsChartTranscripts

Inhibikase Therapeutics Ownership Summary

Inhibikase Therapeutics is owned by 57.48% institutional investors, 13.03% insiders, and 29.50% retail investors. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.06% of its assets in Inhibikase Therapeutics shares.

IKT Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockInhibikase Therapeutics57.48%13.03%29.50%
SectorHealthcare Stocks 279.17%10.51%-189.68%
IndustryBiotech Stocks 63.95%10.67%25.38%

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20254751.61%51,462,7562.80%570.13%313.33%3-
Dec 31, 202431181.82%50,059,3085719.28%2111604.08%30500.00%--100.00%
Sep 30, 202411-8.33%860,2322.84%329.15%5-28.57%2-
Jun 30, 202412-836,496306.94%3469.42%740.00%2-50.00%
Mar 31, 2024129.09%205,558-12.53%-88.26%5-433.33%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.28M3.06%-
Vanguard Institutional Extnd Mkt Idx Tr483.35K0.65%-
Fidelity Extended Market Index153.70K0.21%3.21K
Extended Equity Market Fund K54.50K0.07%740.00
Fidelity Total Market Index52.80K0.07%-7.31K
Vanguard Balanced Index Inv44.36K0.06%-
Fidelity Series Total Market Index38.35K0.05%-
Vanguard Instl Ttl Stck Mkt Idx Tr33.54K0.05%33.54K
Timber Point Global Allocations Instl35.00K0.05%24.00K
Vanguard Instl Ttl Stk Mkt Idx InstlPls33.54K0.05%-

Recent Insider Transactions

DateNameRoleActivityValue
Oct 21, 2024Bellini Roberto-Buy$2.00M
Oct 21, 2024Kush Arvind-Buy$198.65K
Oct 21, 2024Munshi Amit-Buy$500.05K
Aug 16, 2022Werner Milton H. President and CEOBuy$4.00K
May 27, 2022Werner Milton H. President and CEOBuy$4.88K

Insider Transactions Trends

DateBuySell
2025 Q1--
2024 Q43-
2024 Q3--
2024 Q2--
2023 Q2--

IKT Ownership FAQ

Who Owns Inhibikase Therapeutics?

Inhibikase Therapeutics shareholders are primarily institutional investors at 57.48%, followed by 13.03% insiders and 29.49% retail investors. The average institutional ownership in Inhibikase Therapeutics's industry, Biotech Stocks , is 63.95%, which Inhibikase Therapeutics falls below.

Does Blackrock own Inhibikase Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Inhibikase Therapeutics.

Who is the top mutual fund holder of Inhibikase Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Inhibikase Therapeutics shares, with 3.06% of its total shares outstanding invested in 2.28M Inhibikase Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools